Androgens and the ageing male and female

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 2, 2003, Pages 223-236

  Yialamas, Maria A ^a   Hayes, Frances J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Ageing; Libido; Osteoporosis; Post menopausal; Sarcopenia; Testosterone

Indexed keywords

ALBUMIN; ANABOLIC AGENT; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; CLOMIFENE; ESTRADIOL; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; METHYLTESTOSTERONE; PROSTATE SPECIFIC ANTIGEN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; STEROID HORMONE RECEPTOR BLOCKING AGENT; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; TRESTOLONE; UNCLASSIFIED DRUG;

ACNE; AGING; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ASSAY; BODY COMPOSITION; BONE MASS; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG COST; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; EQUILIBRIUM DIALYSIS; ERYTHROPOIESIS; HIRSUTISM; HORMONE ACTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPERVISCOSITY SYNDROME; HYPOGONADISM; LIBIDO DISORDER; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; META ANALYSIS; MUSCLE MASS; MUSCLE STRENGTH; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SEX HORMONE DETERMINATION; SEXUAL FUNCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP APNEA SYNDROME; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; VIRILIZATION; MENOPAUSE; SUPPLEMENTATION; TESTOSTERONE METABOLISM;

EID: 0037700256     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00018-6     Document Type: Review

References (88)

1. Butenandt A. Uber die chemische unterschung der sexual hormones. Z Agnew Chem 1931; 44: 905-908.
2. Fowles D. A profile of older Americans. Washington DC, US Department of Health and Human Services: American Association of Retired Persons and the Administration Ageing, 1997.
3. Vermeulen A, Rubens R & Verdonck L. Testosterone secretion and metabolism in male senescence. Journal of Clinical Endocrinology and Metabolism 1972; 34: 730-735.
4. Purifoy FE, Koopmans LH & Mayes DM. Age differences in serum androgen levels in normal adult males. Human Biology 1981; 53: 499-511.
5. Bremmer WJ, Vitiello MV & Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with ageing in normal men. Journal of Clinical Endocrinology and Metabolism 1983; 56: 1278-1281.
6. Tenover JS, Matsumoto AM, Plymate SR & Bremmer WJ. The effects of ageing in normal men on bioavailable testosterone and luteinizing hormone secretion: Response to clomiphene citrate. Journal of Clinical Endocrinology and Metabolism 1987; 65: 1118-1126.
7. Ferrini RL & Barrett-Connor E. Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. American Journal of Epidemiology 1998; 147: 750-754.
8. Nieschlag E, Lammers U, Freischem CW et al. Reproductive functions in young fathers and grandfathers. Journal of Clinical Endocrinology and Metabolism 1982; 5: 676-681.
9. Harman SM & Tsitouras PD. Reproductive hormones in ageing men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. Journal of Clinical Endocrinology and Metabolism 1980; 51: 35-40.
10. Gray A, Feldman HA, McKinlay JB & Longscope C. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Ageing Study. Journal of Clinical Endocrinology and Metabolism 1991; 73: 1016-1025.
11. Feldman HA, Longcope C, Derby CA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male ageing study. Journal of Clinical Endocrinology and Metabolism 2002; 87: 589-598.
12. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of ageing on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Ageing. Journal of Clinical Endocrinology and Metabolism 2001; 86: 724-731.
13. Veldhuis JD, Rogol AD & Johnson ML. Endogenous opiates modulate the pulsatile secretion of biologically active luteinizing hormone in man. Journal of Clinical Investigation 1983; 72: 2031-2040.
14. Sheckter CB, Matsumoto AM & Bremner WJ. Testosterone administration inhibits gonadotropin secretion by an effect directly on the human pituitary. Journal of Clinical Endocrinology and Metabolism 1989; 68: 397-401.
15. Hayes FJ, DeCruz S, Seminara SB et al. Differential regulation of gonadotropin secretion by testosterone in the human male: Absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion. Journal of Clinical Endocrinology and Metabolism 2001; 86: 53-58.
16. Mulligan T, Iranmanesh A, Gheorghiu S et al. Amplified nocturnal luteinizing hormone (LH) secretory burst frequency with selective attenuation of pulsatile (but not basal) testosterone secretion in healthy aged men: Possible Leydig cell desensitization to endogenous LH signaling - A clinical research center study. Journal of Clinical Endocrinology and Metabolism 1995; 80: 3025-3031.
17. Winters SJ, Sherins RJ & Troen P. The gonadotropin-suppressive activity of androgen is increased in elderly men. Metabolism 1984; 33: 1052-1059.
18. Winters SJ & Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: Evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. Journal of Clinical Endocrinology and Metabolism 1982; 55: 560-565.
19. Mulligan T, Iranmanesh A, Kerzner R et al. Two-week pulsatile gonadotropin releasing hormone infusion unmasks dual (hypothalamic and Leydig cell) defects in the healthy ageing male gonadotropic axis. European Journal of Endocrinology 1999; 141: 257-266.
20. Neaves WB, Johnson L, Porter JC et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in ageing men. Journal of Clinical Endocrinology and Metabolism 1984; 59: 756-763.
21. Longcope C. The effect of human chorionic gonadotropin on plasma steroid levels in young and old men. Steroids 1973; 21: 583-592.
22. Rubens R, Dhont M & Vermeulen A. Further studies on Leydig cell function in old age. Journal of Clinical Endocrinology and Metabolism 1974; 39: 40-45.
23. Summary from the second annual andropause consensus meeting. The Endocrine Society, 2001.
24. Spratt DI, O'Dea LS, Schoenfeld D et al. Neuroendocrine-gonadal axis in men: Frequent sampling of LH, FSH, and testosterone. American Journal of Physiology 1988; 254: E658-E666.
25. Rosner W. Errors in the measurement of plasma free testosterone. Journal of Clinical Endocrinology and Metabolism 1997; 82: 2014-2015.
26. Avila DM, Zoppi S & McPhaul MJ. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer. Journal of Steroid Biochemistry & Molecular Biology 2001; 76: 135-142.
27. Slemenda CW, Longcope C, Zhou L et al. Sex steroids and bone mass in older men. Positive associations with serum oestrogens and negative associations with androgens. Journal of Clinical Investigation 1997; 100: 1755-1759.
28. Bilezikian JP, Morishima A, Bell J & Grumbach MM. Increased bone mass as a result of oestrogen therapy in a man with aromatase deficiency. New England Journal of Medicine 1998; 339: 599-603.
29. Melton L. Epidemiology of fractures. In Melton L & Riggs BL (eds) Osteoporosis: Etiology, Diagnosis and Management. Philadelphia: Lippincott-Raven, 1995, pp 225-247.
30. Finkelstein JS, Klibanski A, Neer RM et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism 1989; 69: 776-783.
31. Hofbauer LC & Khosla S. Androgen effects on bone metabolism: Recent progress and controversies. European Journal of Endocrinology 1999; 140: 271-286.
32. Snyder PJ, Peachey H, Hannousch P et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999; 84: 1966-1972.
33. Bhasin S, Storer TW, Berman N et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine 1996; 335: 1-7.
34. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology and Metabolism 1999; 84: 2647-2653.
35. Webb CM, McNeill JG, Hayward CS et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-1696.
36. Bagatell CJ & Bremner WJ. Androgen and progestagen effects on plasma lipids. Progress in Cardiovascular Diseases 1995; 38: 255-271.
37. Hurley BF, Seals DR, Hagberg JM et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA 1984; 252: 507-513.
38. Friedl KE, Hannan Jr CJ, Jones RE & Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69-74.
39. Tenover JS. Effects of testosterone supplementation in the ageing male. Journal of Clinical Endocrinology and Metabolism 1992; 75: 1092-1098.
40. Morley JE, Perry 3rd HM, Kaiser FE et al. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study. Journal of the American Geriatric Society 1993; 41: 149-152.
41. Lichtenstein MJ, Yarnell JW, Elwood PC et al. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. American Journal of Epidemiology 1987; 126: 647-657.
42. Simon D, Preziosi P, Barrett-Connor E et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: The Telecom Study. Diabetologia 1992; 35: 173-177.
43. Marin P, Holmang S, Jonsson L et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity and Related Metabolic Disorders 1992; 16: 991-997.
44. Marin PHS, Jonsson L et al. Androgen treatment of abdominally obese men. Obesity Research 1993; 1: 245-251.
45. Friedl KE, Jones RE, Hannan Jr CJ & Plymate SR. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Journal of Clinical Endocrinology and Metabolism 1989; 68: 971-975.
46. Cohen JC & Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. Journal of Clinical Endocrinology and Metabolism 1987; 64: 960-963.
47. Wang C, Swedloff RS, Iranmanesh A et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. Journal of Clinical Endocrinology and Metabolism 2000; 85: 2839-2853.
48. Carani C, Zini D, Baldini A et al. Effects of androgen treatment in impotent men with normal and low levels of free testosterone. Archives of Sexual Behavior 1990; 19: 223-234.
49. Buena F, Swerdloff RS, Steiner BS et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertility & Sterility 1993; 59: 1118-1123.
50. Korenman SG, Morley JE, Mooradian AD et al. Secondary hypogonadism in older men: Its relation to impotence. Journal of Clinical Endocrinology and Metabolism 1990; 71: 963-969.
51. Nankin HR & Calkins JH. Decreased bioavailable testosterone in ageing normal and impotent men. Journal of Clinical Endocrinology and Metabolism 1986; 63: 1418-1420.
52. Snyder PJ & Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology and Metabolism 1980; 51: 1335-1339.
53. Handelsman DJ, Mackey MA, Howe C et al. An analysis of testosterone implants for androgen replacement therapy. Clinical Endocrinology (Oxford) 1997; 47: 311-316.
54. Behre HM & Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: Pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. Journal of Clinical Endocrinology and Metabolism 1992; 75: 1204-1210.
55. Cummings DE, Kumar N, Bardin CW et al. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: A potential alternative to testosterone for androgen replacement and male contraception. Journal of Clinical Endocrinology and Metabolism 1998; 83: 4212-4219.
56. Anderson RA, Martin CW, Kung AW et al. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3556-3562.
57. Jockenhovel F, Vogel E, Reinhardt W & Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. European Journal of Medical Research 1997; 2: 293-298.
58. Sandblom RE, Matsumoto AM, Schoene RB et al. Obstructive sleep apnoea syndrome induced by testosterone administration. New England Journal of Medicine 1983; 308: 508-510.
59. Santamaria JD, Prior JC & Fleetham JA. Reversible reproductive dysfunction in men with obstructive sleep apnoea. Clinical Endocrinology (Oxford) 1988; 28: 461-470.
60. Behre HM, Bohmeyer J & Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clinical Endocrinology (Oxford) 1994; 40: 341-349.
61. Report of National Institute on Ageing Advisory Panel on Testosterone Replacement in Men. Journal of Clinical Endocrinology and Metabolism 86 (2001) 4611-4614.
62. Judd HL & Yen SS. Serum androstenedione and testosterone levels during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 1973; 36: 475-481.
63. Judd HL, Lucas WE & Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. American Journal of Obstetrics and Gynecology 1974; 118: 793-798.
64. Horton R & Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. Journal of Clinical Investigation 1966; 45: 301-313.
65. Judd HL, Shamonki IM, Frumar AM & Lagasse LD. Origin of serum estradiol in post-menopausal women. Obstetrics and Gynecology 1982; 59: 680-686.
66. Judd HL, Judd GE, Lucas WE & Yen SS. Endocrine function of the post-menopausal ovary: Concentration of androgens and oestrogens in ovarian and peripheral vein blood. Journal of Clinical Endocrinology and Metabolism 1974; 39: 1020-1024.
67. Chakravarti S, Collins WP, Forecast JD et al. Hormonal profiles after the menopause. British Medical Journal 1976; 2: 784-787.
68. Zumoff B, Strain GW, Miller LK & Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. Journal of Clinical Endocrinology and Metabolism 1995; 80: 1429-1430.
69. Judd HL. Hormonal dynamics associated with the menopause. Clinical Obstetrics and Gynecology 1976; 19: 775-788.
70. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D & Von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. Journal of Clinical Endocrinology and Metabolism 2000; 85: 645-651.
71. Myers LS, Dixen J, Morrissette D et al. Effects of oestrogen, androgen, and progestin on sexual psychophysiology and behavior in post-menopausal women. Journal of Clinical Endocrinology and Metabolism 1990; 70: 1124-1131.
72. Raisz LG, Wiita B, Artis A et al. Comparison of the effects of oestrogen alone and oestrogen plus androgen on biochemical markers of bone formation and resorption in post-menopausal women. Journal of Clinical Endocrinology and Metabolism 1996; 81: 37-43.
73. Need AG, Chatterton BE, Walker CJ et al. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas 1986; 8: 275-280.
74. Need AG, Horowitz M, Bridges A et al. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic post-menopausal women. Archives of Internal Medicine 1989; 149: 57-60.
75. Lyritis GP, Androulakis C, Magiasis B et al. Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. A double-blind clinical trial. Bone and Mineral 1994; 27: 209-217.
76. Chesnut 3rd CH, Ivey JL, Gruber HE et al. Stanozolol in post-menopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. Metabolism 1983; 32: 571-580.
77. Birkenhager JC, Erdtsieck RJ, Zeelenberg J et al. Can nandrolone add to the effect of hormonal replacement therapy in post-menopausal osteoporosis? Bone and Mineral 1992; 18: 251-265.
78. Savvas M, Studd JW, Norman S et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. British Journal of Obstetrics and Gynaecology 1992; 99: 757-760.
79. Watts NB, Notelovitz M, Timmons MC et al. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstetrics and Gynecology 1995; 85: 529-537.
80. Davis SR, Walker KZ & Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in post-menopausal women. Menopause 2000; 7: 395-401.
81. Lovejoy JC, Bray GA, Bourgeois MO et al. Exogenous androgens influence body composition and regional body fat distribution in obese post-menopausal women - A clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996; 81: 2198-2203.
82. Miller K, Corcoran C, Armstrong C et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study. Journal of Clinical Endocrinology and Metabolism 1998; 83: 2717-2725.
83. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. New England Journal of Medicine 2000; 343: 682-688.
84. Sherwin BB, Gelfand MM & Brender W. Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in the surgical menopause. Psychosomatic Medicine 1985; 47: 339-351.
85. Sherwin BB & Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. American Journal of Obstetrics and Gynecology 1985; 151: 153-160.
86. Burger HG, Hailes J, Menelaus M et al. The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results. Maturitas 1984; 6: 351-358.
87. Hulley S, Grady D, Bush T et al. Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
88. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of oestrogen plus progestin in healthy post-menopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.